Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections

Annals of Surgery

Volumn 244, Issue 2, 2006, Pages 204-211

  Malangoni, Mark A ^a,c   Song, James ^b   Herrington, Janet ^b   Choudhri, Shurjeel ^b   Pertel, Peter ^b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b BAYER CORPORATION   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABDOMINAL PAIN; ADULT; ANEMIA; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIAL TRANSMISSION; BACTERIOLOGY; BACTERIUM DETECTION; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMMUNITY; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DEMOGRAPHY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GROUPS BY AGE; HUMAN; HYPOKALEMIA; INFECTION COMPLICATION; INSOMNIA; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIPLE DRUG DOSE; NAUSEA; PELVIS ABSCESS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STANDARD; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VALIDATION PROCESS; WOUND INFECTION;

ABDOMINAL ABSCESS; ADMINISTRATION, ORAL; ADULT; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; APPENDICITIS; AZA COMPOUNDS; BACTERIAL INFECTIONS; CROSS INFECTION; DOUBLE-BLIND METHOD; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL PERFORATION; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; QUINOLINES; SAFETY; STOMACH RUPTURE; TREATMENT OUTCOME;

EID: 33747386215     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000230024.84190.a8     Document Type: Article

References (20)

1. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003;37:997-1005.
2. Condon RE, Wittmann DH. Intraabdominal infections. In: Gorbach S, Blacklow N, Bartlett JG, eds. Infectious Diseases, 2nd ed. Philadelphia: Saunders, 1998:793-800.
3. Levison ME, Bush LM. Peritonitis and other intra-abdominal infections. In: Mandell D, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th ed. Philadelphia: Churchill Livingstone, 2000: 821-856.
4. Nathens AB, Rotstein OD. Antimicrobial therapy for intra-abdominal infection. Am J Surg. 1996;172(suppl):1-6.
5. Berne TV, Yellin AW, Appleman MD, et al. Antibiotic management of surgically treated gangrenous or perforated appendicitis: comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone. Am J Surg. 1982;144:8-13.
6. Yellin AE, Heseltine PN, Berne TV, et al. The role of. Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet. 1985;161:303-307.
7. Solomkin JS, Dellinger EP, Christou NV, et al. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg. 1990;212:581-591.
8. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg. 1991;214:543-549.
9. Falagas ME, Barefoot L, Griffith J, et al. Risk factors leading to clinical failure in the treatment of intra-abdominal infections or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis. 1996;15:913-921.
10. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect. 2002;3:175-233.
11. Golan Y, McDermott LA, Jacobus NV, et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother. 2003;52:208-213.
12. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother. 2004;48:1012-1016.
13. Muller M, Stass H, Brunner M, et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother. 1999;43:2345-2349.
14. Wirtz M, Kleeff J, Swoboda S, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother. 2004;53:875-877.
15. Kim M-K, Nightingale CH. The quinolones: pharmacokinetics and pharmacodynamics of the fluoroquinolones. In: Andriole VT, ed. The Quinolones, San Diego: Academic Press, 2000:169-202.
16. Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol. 2002;53:232-237.
17. Stass H, Kubitza D, von Bergmann K, et al. No dose adjustment is needed for patients with hepatic impairment receiving oral moxifloxacin [Abstract P0771]. Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, 1999.
18. Merlino JI, Malangoni MA, Smith CM, et al. Prospective randomized trials affect the outcomes of intraabdominal infection. Ann Surg. 2001;233:859-866.
19. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections: the intra-abdominal infection study group. Ann Surg. 1996;223:303-315.
20. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections. Ann Surg. 2000;232:254-262.